Skip to main
ALKS
ALKS logo

Alkermes (ALKS) Stock Forecast & Price Target

Alkermes (ALKS) Analyst Ratings

Based on 24 analyst ratings
Buy
Strong Buy 29%
Buy 21%
Hold 46%
Sell 4%
Strong Sell 0%

Bulls say

Alkermes PLC demonstrated strong financial performance in 4Q24, with consolidated non-GAAP diluted EPS rising to $1.05, a substantial increase from $0.22 in the prior year’s quarter. The company reported total revenues of $430.0 million, reflecting a 13.9% year-over-year growth from $377.5 million, and net sales of proprietary products surged to $307.7 million, exceeding expectations significantly. Additionally, Alkermes is capitalizing on successful Phase 2 clinical trial results for TAK-861, which indicates promising advancements in addressing unmet medical needs, further solidifying its growth trajectory.

Bears say

Alkermes PLC has faced a notable decline in its manufacturing and royalty revenues, dropping to $122.3 million in the fourth quarter of 2024 compared to $135.5 million the previous year, signaling potential issues in its revenue generation strategy. Management's guidance for 2025 indicates a significant reduction in expected EBITDA, forecasting approximately $200 million rather than the previously anticipated $450 million, reflecting deteriorating profitability metrics. Additionally, the impending expiration of royalty agreements and declining performance in the base business further suggest a challenging growth outlook, which has adversely affected the company's valuation projections and overall financial stability.

Alkermes (ALKS) has been analyzed by 24 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 21% recommend Buy, 46% suggest Holding, 4% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alkermes and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alkermes (ALKS) Forecast

Analysts have given Alkermes (ALKS) a Buy based on their latest research and market trends.

According to 24 analysts, Alkermes (ALKS) has a Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $38.29, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $38.29, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alkermes (ALKS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.